![Auswahl von Statinen vor dem Hintergrund neu verfasster Lipidleitlinien - 04 - 2020 - Heftarchiv - AMT Auswahl von Statinen vor dem Hintergrund neu verfasster Lipidleitlinien - 04 - 2020 - Heftarchiv - AMT](https://www.arzneimitteltherapie.de/_Resources/Persistent/8/b/1/9/8b19b93cb7a7a159801aeef75ff97af9398b1c39/lipp-rosuvastatin_01_converted_eps.png)
Auswahl von Statinen vor dem Hintergrund neu verfasster Lipidleitlinien - 04 - 2020 - Heftarchiv - AMT
Fractional Flow Reserve-Guided SYNTAX Score for Risk Assessment in Multi-vessel Coronary Artery Disease
![IJMS | Free Full-Text | Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter? IJMS | Free Full-Text | Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?](https://www.mdpi.com/ijms/ijms-23-09326/article_deploy/html/images/ijms-23-09326-g003.png)
IJMS | Free Full-Text | Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?
![Approximate Equivalent Rosuvastatin Doses for Temporary Statin Interchange Programs | Semantic Scholar Approximate Equivalent Rosuvastatin Doses for Temporary Statin Interchange Programs | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/37efcaf1312c5ca35047d184682c7857630cce38/4-Table1-1.png)
Approximate Equivalent Rosuvastatin Doses for Temporary Statin Interchange Programs | Semantic Scholar
![Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients](https://static-02.hindawi.com/articles/isrn/volume-2013/146579/figures/146579.fig.003.jpg)
Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients
![Prescribed Daily Doses (PDDs) of Hypolipidaemic Agents in South Africa with Emphasis on HMG CoA Reductase Inhibitors | Semantic Scholar Prescribed Daily Doses (PDDs) of Hypolipidaemic Agents in South Africa with Emphasis on HMG CoA Reductase Inhibitors | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c9eedbe38927fda118d3f7368ad657b72bc2a49f/2-Table1-1.png)
Prescribed Daily Doses (PDDs) of Hypolipidaemic Agents in South Africa with Emphasis on HMG CoA Reductase Inhibitors | Semantic Scholar
In order to assist in converting your patient from a Non-preferred statin to the Preferred statin on Arkansas Medicaid, the foll
![Approximate Equivalent Rosuvastatin Doses for Temporary Statin Interchange Programs | Semantic Scholar Approximate Equivalent Rosuvastatin Doses for Temporary Statin Interchange Programs | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/37efcaf1312c5ca35047d184682c7857630cce38/3-Table1-1.png)
Approximate Equivalent Rosuvastatin Doses for Temporary Statin Interchange Programs | Semantic Scholar
![Statins in Chronic Kidney Disease and Dialysis: Clinical Trials, Mechanisms, Dosing, and Treatment Recommendations | National Lipid Association Online Statins in Chronic Kidney Disease and Dialysis: Clinical Trials, Mechanisms, Dosing, and Treatment Recommendations | National Lipid Association Online](https://www.lipid.org/sites/default/files/images/Table%201%20Lerma.jpg)
Statins in Chronic Kidney Disease and Dialysis: Clinical Trials, Mechanisms, Dosing, and Treatment Recommendations | National Lipid Association Online
![Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer | British Journal of Cancer Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2014.283/MediaObjects/41416_2014_Article_BFbjc2014283_Fig1_HTML.jpg)
Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer | British Journal of Cancer
![Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients](https://static-02.hindawi.com/articles/isrn/volume-2013/146579/figures/146579.fig.001.jpg)